Successive sebopsoriasis, erysipelas and Koebner phenomenon.
Viguier
Manuelle
M
Department of Dermatology, Université Paris Diderot-Paris 7, and Hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris, Paris, France.
Bachelez
Hervé
H
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001685:Biological Factors / Q000009:adverse effects*; D012628:Dermatitis, Seborrheic / Q000139:chemically induced*; D004886:Erysipelas / Q000139:chemically induced*; D000068800:Etanercept; D005148:Facial Dermatoses / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications* / Q000188:drug therapy; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001685:Biological Factors; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept; C472181:efalizumab